Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Kushi Kullar who wrote (5747)	10/9/1998 1:27:00 PM
From: Harold Engstrom	Read Replies (1) \| Respond to of 9719

Vical is not the kind of company I usually buy. Rick would be a far better source for an opinion on Vical, if he follows it or follows gene therapy trends in general. Rick has almost caused me to deviate from my normal investment strategy and purchase BTRN. My strategy is to buy companies with solid science, the ability to pull a compound through the clinic, good manufacturing and conservative financial practices. This means that companies I would invest in usually make a profit and are fairly well know. This also means that I never have a 50-bagger within 3 years, but also get decent returns on what I do invest in. Rick Harmon, on the other hand, has expertise in identifying larval and pupal stage biotechs that hold great promise and are much more likely than average to turn into the kind of company that I would invest in. Maybe Vical is one of those companies. Any thoughts Rick?